BRAF and metastatic melanoma: The drug was approved by FDA for the treatment of patients both with BRAF V600 wild-type unresectable and BRAF V600 mutation-positive metastatic melanoma in addition to combination treatment with ipilimumab (anti-CTLA-4 antibody).